GLU-IMAGE · Glutamate dynamics during visual stimulation and ketamine challenge in the human brain
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-07-01 → 2021-06-30
- EU contribution
- €186,167
- Participants
- 1
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Glutamate dynamics during visual stimulation and ketamine challenge in the human brain
Impaired glucose homeostasis and mitochondrial dysfunction are key components of neurodegenerative, metabolic, and psychiatric diseases, such as Alzheimer’s, schizophrenia, and depression. Therefore, an affordable, reliable, and easy-to-apply method to measure brain glucose metabolism is emergently needed. The development of the noninvasive technique, which allows objective, dynamic and longitudinal tracking of brain alterations in health, disease, and aging was a primary goal of our work. To date, techniques such as PET allow to solely measure glucose consumption but do not allow to quantify the downstream metabolism of glucose, affected in the brain diseases. To address this issue, we have focused on developing novel quantitative and noninvasive glutamate MR measures. Glutamate (Glu) is the most abundant neurotransmitter and the downstream component of the Glc metabolism thus considered a key marker of oxidative brain metabolism. Indeed, glutamatergic impairments are fundamentally involved in the pathophysiology of several neurological and neuropsychiatric disorders and are a significant target of emerging therapies. A novel ground-breaking accelerated method for ultra-short echo time proton (1H) MRS imaging (UTE-MRSI), developed and fine-tuned for the project by our team at the High-field MR Centre, Medical University of Vienna, indeed offers critical sensitivity improvements for Glu quantification compared to conventional SV-MRS and previous MRSI approaches. Hence, the proposed improved version of the UTE-MRSI technique will allow image-based multi-slice measurements of baseline Glu concentration and tracking Glu responses to brain activation. These measures are essential for accurate mapping of metabolic changes and treatment responses in severe neurological and psychiatric brain diseases such as depression, schizophrenia, epilepsy, and Alzheimer’s disease. In the current project, we established a highly reproducible MRSI technique to map and visualize endogenous Glu in the resting and activated human brain regions. We significantly improved an innovative noninvasive UTE-MRSI method that provided superior spatial resolution and coverage compared to SV-MRS, and we validated its feasibility to detect Glu oscillations in the resting and activated human brain.
Data: CORDIS, © European Union
Project objective
While clinical experience confirmed ketamine, a glutamate (Glu) N-methyl-D-aspartate receptor antagonist, as a potent therapy of treatment-resistant major depressive disorder (TRD), the exact mechanism of ketamine’s action in the brain is unclear. Thus, a method to reliably and reproducibly monitor minute changes in Glu metabolism in the human brain is urgently needed to understand ketamine dynamics in vivo. So far, the pioneering work at the Medical University Vienna (MUW) showed ketamine-induced increase of vascular and metabolic responses measured as blood oxygenation level dependent (BOLD) signals in healthy subjects in thalamus, insula and anterior cingulate cortex (ACC), while others observed elevated glucose uptake using positron emission tomography, suggesting higher energetic demands and Glu response after ketamine infusion. Yet, a reliable and non-invasive method for direct monitoring of pharmacologically-induced dynamic Glu changes is still missing. Our group at MUW has recently developed a novel ground-breaking accelerated method for ultra-short echo time MRS imaging (UTE-MRSI) providing optimal Glu measures with critical sensitivity improvements compared to conventional proton single-voxel MRS (SV-MRS) and previously utilized MRSI approaches. Our method allows monitoring of Glu responses selectively in activated voxels and overcomes low spatial resolution, and limited coverage of SV-MRS that is the current gold standard for measurement of Glu concentrations and its dynamic changes in vivo (functional SV-MRS). The further improvement of UTE-MRSI by the implementation of the novel real-time motion correction will boost its applicability in clinical human studies. Thus, our UTE-MRSI will offer image-based multi-slice measurements of baseline Glu concentrations and its responses to ketamine administration with the potential to clarify ketamine’s mechanism of action in patients with TRD, and will allow monitoring of other novel glutamatergic therapies.
Original text from CORDIS.
Participants
- MEDIZINISCHE UNIVERSITAET WIEN · WienCoordinatorAustria
Links
- View on CORDIS
- DOI: 10.3030/846793
- https://www.meduniwien.ac.at/web/forschung/projekte/glutamate-dynamics-during-visual-stimulation-and-ketamine-challenge-in-the-human-brain/home/
Data: CORDIS, © European Union
